Clinical Trial Update: Stereotactic Intracerebral Injection of IPSC-DAPs in Patients with Parkinson's Disease [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating stereotactic intracerebral injection of IPSC-DAPs for Parkinson disease; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• IPSC-DAPs

Snippet

Sponsor: iCamuno Biotherapeutics Ltd. | Conditions: Parkinson Disease | Phase 1 | Status: NOT_YET_RECRUITING